Summary

Results from the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 51 [ATLAS ACS 2-TIMI 51; NCT00809965] Trial showed that rivaroxaban significantly reduced the risk of cardiovascular death, myocardial infarction, and stroke in acute coronary syndrome patients.